Limiting cardiovascular events associated with HIV and antiretroviral therapy

AIDS. 2017 Nov 28;31(18):2551-2553. doi: 10.1097/QAD.0000000000001676.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Retroviral Agents / adverse effects
  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Cardiovascular Diseases / chemically induced*
  • HIV Infections / drug therapy*
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Middle Aged
  • Oxazines
  • Piperazines
  • Pyridones
  • Randomized Controlled Trials as Topic
  • Risk Factors

Substances

  • Anti-Retroviral Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir